Physician profile
Albert L Smith
NPI 1619975380
$3,180.50
in general payments reported to CMS, 2019-2025
24 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $604 · 2021: $174 · 2022: $133 · 2023: $317 · 2024: $721 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.07 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $886.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $471.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $361.90 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $173.59 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $155.00 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.06 | 2019-2020 | |
| Pfizer INC. | $115.41 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $99.58 | 2019-2024 | |
| Exact Sciences Corporation | $87.27 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $83.86 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $83.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $82.58 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $79.60 | 2024-2025 | |
| Amarin Pharma, INC. | $78.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.73 | 2019-2023 | Xarelto |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.98 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $35.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2024-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $22.33 | 2019 | |
| Phadia US INC. | $21.42 | 2023 | Immunocap |
| Genentech USA, INC. | $21.12 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.38 | 2021 | |
| Dexcom, INC. | $19.86 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $19.67 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.